Prazosin‐induced patient‐derived GIC apoptosis and inhibition of glioblastoma growth in vivo through a PKCδ‐dependent mechanism of action, associated with the well‐established and documented use of this drug in clinical settings, opens a promising possibility for its use in glioblastoma treatment. Here, PRKCD is linked to glioblastoma.